Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstroms Macroglobulinemia: A Multicenter Trial of the European Myeloma Network

NCT00832234 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.

NCT NCT00832234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00832234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstroms Macroglobulinemia: A Multicenter Trial of the European Myeloma Network
Lead sponsor
European Myeloma Network B.V.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
June 30, 2013
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstroms macroglobulinemia